Key result
Ceftaroline fosamil for empiric cSSTI therapy resulted in a 24.6% early discharge rate and €6763 cost per patient, providing comparable early response and costs to other relevant antibiotic options.
Why the study?
Complicated skin and soft tissue infections carry high healthcare resource use and costs, making the appropriate choice of immediate empiric intravenous antibiotic therapy crucial.
Does ceftaroline fosamil provide comparable early discharge rates and costs compared to other IV antibiotics in hospitalized adults with cSSTI?
Does ceftaroline fosamil provide comparable early discharge rates and costs compared to other IV antibiotics in hospitalized adults with cSSTI?
Ceftaroline fosamil is an economically acceptable empiric therapy for cSSTI in the Spanish National Health System, offering comparable early discharge rates and costs to other standard IV antibiotics.
Answers are grounded in this paper and cite their sources.
Supports ceftaroline consideration for cSSTI cost efficiency; leaves open randomized validation of outcomes.
Purpose: Complicated skin and soft tissue infections (cSSTI) are associated with high healthcare resource use and costs. The emergency nature of cSSTI hospitalizations requires starting immediate empiric intravenous (IV) antibiotic treatment, making the appropriate choice of initial antibiotic therapy crucial. Patients and Methods: The use of ceftaroline fosamil (CFT) as an alternative to other IV antibiotic therapies for the empiric treatment of hospitalized adults with cSSTI (vancomycin, linezolid, daptomycin, cloxacillin, tedizolid) was evaluated through cost consequences analysis. The model structure was a decision tree accounting for four different pathways: patients demonstrating early response (ER) either discharged early (with oral antibiotic) or remaining in hospital to continue the initial therapy; non-responders either remaining on the initial IV therapy or switching to a second-line antibiotic. The model perspective was the Spanish National Health System. Results: CFT resulted in average percentage of patients discharged early (PDE) of 24.6% (CI 19.49-30.2%) with average total cost per patient of €6763 (€6268-€7219). Vancomycin, linezolid, daptomycin and tedizolid resulted in average PDE of 22% (17.34-27.09%), 26.4% (20.5-32.32%), 28.6% (22.08-35.79%) and 26.5% (20.39-33.25%), respectively, for a total cost per patient of €6,619 (€5,902-€6,929), €6,394 (€5,881-€6,904), €6,855 (€5,800-€7,410) and €7,173 (€6,608-€7,763), respectively. Key model drivers were ER and antibiotic treatment duration, with hospital costs accounting for over 83% of the total expenditures. Conclusion: Given its clinical and safety profile, CFT is an acceptable choice for cSSTI empiric therapy providing comparable ER and costs to other relevant antibiotic options.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied Complicated skin and soft tissue infections (cSSTI). Ceftaroline fosamil vs. Vancomycin, linezolid, daptomycin, cloxacillin, tedizolid was evaluated on Average percentage of patients discharged early (PDE) and average total cost per patient. Ceftaroline fosamil for empiric cSSTI therapy resulted in a 24.6% early discharge rate and €6763 cost per patient, providing comparable early response and costs to other relevant antibiotic options.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: